Skip to main content
logo
Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
30.50
-0.97 (-3.08%)
Sep 23, 2026, 9:25 AM EDT - Market open

Caris Life Sciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
989.61812.03412.26306.13258.49
Revenue Growth
85.37%96.97%34.67%18.43%-
Gross Profit
691.23541.04180.4391.2680.02
Operating Income
153.2645.11-257.12-319.55-315.76
Net Income
105.14-537.96-378.26-462.53-399.83
Earnings Per Share
0.37-3.22-10.66-13.24-11.98
EPS Growth
-----

Revenue by Segment
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Molecular Profiling Services
952.77766.72349.12278.75238.6181.5
Pharma Research and Development Services
36.8445.3163.1527.3819.910.8
Revenue (Total)
989.61812.03412.26306.13258.49-

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
793.12798.5766.15121.59409.62
Total Debt
452.4427.69424.26217.11270.87
Net Cash (Debt)
340.71370.88-358.11-95.52138.75
Net Cash Growth
12.74%----
Net Cash Per Share
1.202.22-10.09-2.734.16

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
168.5683.16-245.2-276.1-285.71
Capital Expenditures
-44.6-16.26-8.44-22.32-42.26
Free Cash Flow
123.9666.9-253.64-298.42-327.96
Free Cash Flow Growth
-----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
69.85%66.63%43.77%29.81%30.96%
Operating Margin
15.49%5.56%-62.37%-104.38%-122.16%
Pretax Margin
10.61%-8.38%-68.38%-111.53%-124.12%
Profit Margin
10.62%-66.25%-91.75%-151.09%-154.68%
FCF Margin
12.53%8.24%-61.52%-97.48%-126.88%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Forward PE
112.19294.73---
P/FCF Ratio
71.75113.80---
PS Ratio
8.999.37---